Literature DB >> 22791353

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.

A J Johnson, Y-Y Yeh, L L Smith, A J Wagner, J Hessler, S Gupta, J Flynn, J Jones, X Zhang, R Bannerji, M R Grever, J C Byrd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22791353      PMCID： PMC3645353          DOI： 10.1038/leu.2012.144

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Selective role of PI3K delta in neutrophil inflammatory responses.

Authors:  Chanchal Sadhu; Ken Dick; William T Tino; Donald E Staunton
Journal:  Biochem Biophys Res Commun       Date:  2003-09-05       Impact factor: 3.575

2.  Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.

Authors:  J A Woyach; G Lozanski; A S Ruppert; A Lozanski; K A Blum; J A Jones; J M Flynn; A J Johnson; M R Grever; N A Heerema; J C Byrd
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

3.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

4.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

Authors:  Kamil Paruch; Michael P Dwyer; Carmen Alvarez; Courtney Brown; Tin-Yau Chan; Ronald J Doll; Kerry Keertikar; Chad Knutson; Brian McKittrick; Jocelyn Rivera; Randall Rossman; Greg Tucker; Thierry Fischmann; Alan Hruza; Vincent Madison; Amin A Nomeir; Yaolin Wang; Paul Kirschmeier; Emma Lees; David Parry; Nicole Sgambellone; Wolfgang Seghezzi; Lesley Schultz; Frances Shanahan; Derek Wiswell; Xiaoying Xu; Quiao Zhou; Ray A James; Vidyadhar M Paradkar; Haengsoon Park; Laura R Rokosz; Tara M Stauffer; Timothy J Guzi
Journal:  ACS Med Chem Lett       Date:  2010-05-17       Impact factor: 4.345

5.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

6.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:  Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

7.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

8.  Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Authors:  Thomas S Lin; Amy S Ruppert; Amy J Johnson; Beth Fischer; Nyla A Heerema; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; Weihong Hu; Mollie E Moran; Sarah M Mitchell; Lisa L Smith; Amy J Wagner; Chelsey A Raymond; Larry J Schaaf; Mitch A Phelps; Miguel A Villalona-Calero; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.

Authors:  Michael R Grever; David M Lucas; Amy J Johnson; John C Byrd
Journal:  Best Pract Res Clin Haematol       Date:  2007-09       Impact factor: 3.020

10.  Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

Authors:  Syed-Rehan A Hussain; David M Lucas; Amy J Johnson; Thomas S Lin; Alan P Bakaletz; Vinh X Dang; Serge Viatchenko-Karpinski; Amy S Ruppert; John C Byrd; Periannan Kuppusamy; Elliott D Crouser; Michael R Grever
Journal:  Blood       Date:  2008-01-11       Impact factor: 22.113
View more
  40 in total

1.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Authors:  Muhammed H Rahaman; Yingyi Yu; Longjin Zhong; Julian Adams; Frankie Lam; Peng Li; Ben Noll; Robert Milne; Jun Peng; Shudong Wang
Journal:  Invest New Drugs       Date:  2018-09-08       Impact factor: 3.850

Review 3.  Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Authors:  Alexey V Danilov
Journal:  Clin Ther       Date:  2013-09       Impact factor: 3.393

Review 4.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

Review 5.  Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.

Authors:  Joseph Maly; James S Blachly
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

6.  Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Authors:  Alexey V Danilov; Shanhu Hu; Bernardo Orr; Kristina Godek; Lisa Maria Mustachio; David Sekula; Xi Liu; Masanori Kawakami; Faye M Johnson; Duane A Compton; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2016-08-22       Impact factor: 6.261

Review 7.  Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors:  James S Blachly; John C Byrd
Journal:  Leuk Lymphoma       Date:  2013-07-29

8.  Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.

Authors:  Tri K Nguyen; Steven Grant
Journal:  Mol Cancer Ther       Date:  2013-12-20       Impact factor: 6.261

Review 9.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 10.  Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date.

Authors:  Kyle Crassini; Stephen P Mulligan; O Giles Best
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.